Recipient, donor, and HCT characteristics stratified by recipient–donor iciHHV-6 status
| Characteristic . | HCT recipient–donor iciHHV-6 status . | |||
|---|---|---|---|---|
| R−/D− (n=4232) . | R+/D− (n=47) . | R−/D+ (n=27) . | R+/D+ (n=13) . | |
| Age of recipient, median (IQR) | 44 (31-54) | 43 (32-56) | 41 (31-53) | 41 (34-54) |
| Age of donor, median (IQR) | 38 (28-48) | 34 (26-47) | 36 (28-50) | 49 (31-59) |
| Sex of recipient | ||||
| Female | 1738 (41.1) | 14 (29.8) | 13 (48.1) | 6 (46.2) |
| Male | 2494 (58.9) | 33 (70.2) | 14 (51.9) | 7 (53.8) |
| Sex of donor | ||||
| Female | 1910 (45.1) | 23 (48.9) | 9 (33.3) | 8 (61.5) |
| Male | 2318 (54.9) | 24 (51.1) | 18 (66.7) | 5 (38.5) |
| Sex mismatch | 1930 (45.6) | 23 (48.9) | 12 (44.4) | 6 (46.2) |
| Race of recipient | ||||
| White | 3512 (85.0) | 46 (97.9) | 23 (92) | 13 (100) |
| African American | 75 (1.8) | 1 (2.1) | 0 | 0 |
| Other | 546 (13.2) | 0 | 3 (8) | 0 |
| Unknown | 99 | 0 | 2 | 0 |
| Race of donor | ||||
| White | 2235 (84.2) | 26 (92.8) | 11 (100) | 12 (100) |
| African American | 61 (2.3) | 1 (3.6) | 0 | 0 |
| Other | 357 (13.5) | 1 (3.6) | 0 | 0 |
| Unknown | 1579 | 19 | 16 | 1 |
| Underlying disease type of recipient* | ||||
| Acute leukemia | 1689 (39.9) | 27 (57.4) | 12 (44.4) | 3 (23.1) |
| Aplastic anemia | 111 (2.6) | 1 (2.1) | 0 | 1 (7.7) |
| Cancer, nonhematologic | 21 (0.5) | 0 | 0 | 0 |
| Chronic leukemia | 1096 (25.9) | 10 (21.3) | 9 (33.3) | 4 (30.8) |
| Lymphoma, Hodgkin | 98 (2.3) | 0 | 2 (7.4) | 0 |
| Lymphoma, non-Hodgkin | 265 (6.3) | 2 (4.3) | 1 (3.7) | 3 (23.1) |
| MDS | 75 (1.8) | 0 | 0 | 1 (7.7) |
| Multiple myeloma | 215 (5.1) | 2 (4.3) | 1 (3.7) | 0 |
| Noncancer | 662 (15.6) | 5 (10.6) | 2 (7.4) | 1 (7.7) |
| CMV serostatus of recipient | ||||
| Positive | 2289 (54.3) | 20 (42.6) | 17 (63.0) | 8 (61.5) |
| Negative | 1928 (45.7) | 27 (57.4) | 10 (37.0) | 5 (38.5) |
| Unknown | 15 | 0 | 0 | 0 |
| CMV serostatus of donor | ||||
| Positive | 1724 (40.1) | 13 (27.7) | 14 (51.9) | 10 (76.9) |
| Negative | 2501 (59.2) | 34 (72.3) | 13 (48.1) | 3 (23.1) |
| Unknown | 7 | 0 | 0 | 0 |
| Recipient or donor CMV positive | 2820 (66.6) | 27 (57.4) | 22 (81.5) | 10 (76.9) |
| Recipient–donor relation | ||||
| Related | 2017 (47.7) | 21 (44.7) | 7 (25.9) | 12 (92.3) |
| Unrelated | 2215 (52.3) | 26 (55.3) | 20 (74.1) | 1 (7.7) |
| HLA-match† | ||||
| HLA-matched | 3279 (77.5) | 40 (85.1) | 19 (70.4) | 10 (76.9) |
| HLA-mismatched | 953 (22.5) | 7 (14.9) | 8 (29.6) | 3 (23.1) |
| Underlying disease severity‡ | ||||
| More advanced | 1696 (40.1) | 18 (38.3) | 14 (51.9) | 6 (46.2) |
| Less advanced | 2536 (59.9) | 29 (61.7) | 13 (48.1) | 7 (53.8) |
| Conditioning regimen¶ | ||||
| Myeloablative | 2877 (68.0) | 33 (70.2) | 20 (74.1) | 9 (69.2) |
| Nonmyeloablative or reduced intensity | 1355 (32.0) | 14 (29.8) | 7 (25.9) | 4 (30.8) |
| Cell source | ||||
| Peripheral blood | 2133 (50.4) | 26 (55.3) | 11 (40.7) | 5 (38.5) |
| Bone marrow | 2099 (49.6) | 21 (44.7) | 16 (59.3) | 8 (61.5) |
| Year of treatment | ||||
| ≥2000 | 2522 (59.6) | 28 (59.6) | 16 (59.3) | 3 (23.1) |
| <2000 | 1710 (40.4) | 19 (40.4) | 11 (40.7) | 10 (76.9) |
| Characteristic . | HCT recipient–donor iciHHV-6 status . | |||
|---|---|---|---|---|
| R−/D− (n=4232) . | R+/D− (n=47) . | R−/D+ (n=27) . | R+/D+ (n=13) . | |
| Age of recipient, median (IQR) | 44 (31-54) | 43 (32-56) | 41 (31-53) | 41 (34-54) |
| Age of donor, median (IQR) | 38 (28-48) | 34 (26-47) | 36 (28-50) | 49 (31-59) |
| Sex of recipient | ||||
| Female | 1738 (41.1) | 14 (29.8) | 13 (48.1) | 6 (46.2) |
| Male | 2494 (58.9) | 33 (70.2) | 14 (51.9) | 7 (53.8) |
| Sex of donor | ||||
| Female | 1910 (45.1) | 23 (48.9) | 9 (33.3) | 8 (61.5) |
| Male | 2318 (54.9) | 24 (51.1) | 18 (66.7) | 5 (38.5) |
| Sex mismatch | 1930 (45.6) | 23 (48.9) | 12 (44.4) | 6 (46.2) |
| Race of recipient | ||||
| White | 3512 (85.0) | 46 (97.9) | 23 (92) | 13 (100) |
| African American | 75 (1.8) | 1 (2.1) | 0 | 0 |
| Other | 546 (13.2) | 0 | 3 (8) | 0 |
| Unknown | 99 | 0 | 2 | 0 |
| Race of donor | ||||
| White | 2235 (84.2) | 26 (92.8) | 11 (100) | 12 (100) |
| African American | 61 (2.3) | 1 (3.6) | 0 | 0 |
| Other | 357 (13.5) | 1 (3.6) | 0 | 0 |
| Unknown | 1579 | 19 | 16 | 1 |
| Underlying disease type of recipient* | ||||
| Acute leukemia | 1689 (39.9) | 27 (57.4) | 12 (44.4) | 3 (23.1) |
| Aplastic anemia | 111 (2.6) | 1 (2.1) | 0 | 1 (7.7) |
| Cancer, nonhematologic | 21 (0.5) | 0 | 0 | 0 |
| Chronic leukemia | 1096 (25.9) | 10 (21.3) | 9 (33.3) | 4 (30.8) |
| Lymphoma, Hodgkin | 98 (2.3) | 0 | 2 (7.4) | 0 |
| Lymphoma, non-Hodgkin | 265 (6.3) | 2 (4.3) | 1 (3.7) | 3 (23.1) |
| MDS | 75 (1.8) | 0 | 0 | 1 (7.7) |
| Multiple myeloma | 215 (5.1) | 2 (4.3) | 1 (3.7) | 0 |
| Noncancer | 662 (15.6) | 5 (10.6) | 2 (7.4) | 1 (7.7) |
| CMV serostatus of recipient | ||||
| Positive | 2289 (54.3) | 20 (42.6) | 17 (63.0) | 8 (61.5) |
| Negative | 1928 (45.7) | 27 (57.4) | 10 (37.0) | 5 (38.5) |
| Unknown | 15 | 0 | 0 | 0 |
| CMV serostatus of donor | ||||
| Positive | 1724 (40.1) | 13 (27.7) | 14 (51.9) | 10 (76.9) |
| Negative | 2501 (59.2) | 34 (72.3) | 13 (48.1) | 3 (23.1) |
| Unknown | 7 | 0 | 0 | 0 |
| Recipient or donor CMV positive | 2820 (66.6) | 27 (57.4) | 22 (81.5) | 10 (76.9) |
| Recipient–donor relation | ||||
| Related | 2017 (47.7) | 21 (44.7) | 7 (25.9) | 12 (92.3) |
| Unrelated | 2215 (52.3) | 26 (55.3) | 20 (74.1) | 1 (7.7) |
| HLA-match† | ||||
| HLA-matched | 3279 (77.5) | 40 (85.1) | 19 (70.4) | 10 (76.9) |
| HLA-mismatched | 953 (22.5) | 7 (14.9) | 8 (29.6) | 3 (23.1) |
| Underlying disease severity‡ | ||||
| More advanced | 1696 (40.1) | 18 (38.3) | 14 (51.9) | 6 (46.2) |
| Less advanced | 2536 (59.9) | 29 (61.7) | 13 (48.1) | 7 (53.8) |
| Conditioning regimen¶ | ||||
| Myeloablative | 2877 (68.0) | 33 (70.2) | 20 (74.1) | 9 (69.2) |
| Nonmyeloablative or reduced intensity | 1355 (32.0) | 14 (29.8) | 7 (25.9) | 4 (30.8) |
| Cell source | ||||
| Peripheral blood | 2133 (50.4) | 26 (55.3) | 11 (40.7) | 5 (38.5) |
| Bone marrow | 2099 (49.6) | 21 (44.7) | 16 (59.3) | 8 (61.5) |
| Year of treatment | ||||
| ≥2000 | 2522 (59.6) | 28 (59.6) | 16 (59.3) | 3 (23.1) |
| <2000 | 1710 (40.4) | 19 (40.4) | 11 (40.7) | 10 (76.9) |
Data are presented as No. (%) unless otherwise indicated. Percentage was calculated based on the number of known observations.
iciHHV-6, inherited chromosomally integrated HHV-6; IQR, interquartile range.
Non-hematologic cancers included breast cancer, sarcoma, neuroblastoma, medulloblastoma, melanoma, cervical cancer, and renal cell carcinoma. Non-cancer underlying disease included primary immunodeficiencies and other non-malignant hematologic disorders.
HLA-match indicates 10/10 allele or antigen match.
More advanced underlying disease refers to diagnoses other than acute myeloid leukemia, acute lymphoblastic leukemia, or lymphoma in first remission, chronic myeloid leukemia in chronic phase, and refractory anemia without excess blasts.
Myeloablative regimens included: any regimen containing ≥800 cGY TBI, any regimen containing carmustine/etoposide/cytarabine/melphalan (BEAM), or any regimen containing busulfan/cyclophosphamide with or without antithymocyte globulin.